FILE- In this April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly’s new COVID-19 treatment helped the drugmaker’s fourth-quarter profit surge even though U.S. regulators approved its use late in the quarter. The antibody treatment bamlanivimab brought in $871 million in sales for Lilly after the Food and Drug Administration authorized emergency use in November 2020 for patients with mild-to-moderate COVID-19. . (AP Photo/Darron Cummings, File)
Featured Photo Galleries
